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Reply to Mori
TO THE EDITOR—We thank Mori for his
correspondence [1]; we agree that circu-
lating neutralizing immunoglobulin G
(IgG) antibodies are most likely responsi-
ble for the prevention of abundant inﬂu-
enza A(H5N1) virus replication in the
olfactory mucosa of vaccinated ferrets.
This lack of virus replication prevented
central nervous system (CNS) invasion
via the olfactory nerve in our ferret
model [2].
Within the nasal cavity, inﬂuenza virus-
es can infect and replicate in the respiratory
mucosa, olfactory mucosa, or both. Ferret
studies have shown that both seasonal
H3N2 and 2009 pandemic H1N1 viruses
replicate predominantly in the respiratory
mucosa, although replication is also
detected within the olfactory mucosa. In
contrast, highly pathogenic avian inﬂuenza
H5N1 virus predominantly replicates in
the olfactory mucosa and only in a few
cells in the respiratory mucosa [3, 4].
Our study suggests that virus replica-
tion within the olfactory mucosa was
efﬁciently reduced or blocked by vaccine-
induced IgG antibodies, thereby preventing
CNS invasion via the olfactory nerve. How-
ever, this does not necessarily mean that
the transport of IgG from the circulation
to the olfactory mucosa is efﬁcient. First
of all, we used a homologues vaccination
and challenge approach—a perfect match.
We did not quantify the concentration of
neutralizing IgG in the olfactory mucosa,
so it might be that low concentrations
were sufﬁcient for virus neutralization. In
addition, even though this vaccination ap-
proach generates cross-reactivity to other
H5 clades [5], the ability to prevent virus
spread to the CNS via the olfactory nerve
of other H5 viruses remains to be deter-
mined. Second, in the same study, oselta-
mivir was not able to reduce or block
virus replication enough to prevent virus
spread to the CNS. Although virus-speciﬁc
IgG and oseltamivir have different mecha-
nisms to block virus replication, both IgG
and oseltamivir have to enter the olfactory
mucosa via the circulation. This might in-
dicate that the fenestrated phenotype of
blood vessels within the olfactory mucosa
does not support transport of all compo-
nents from the circulation. Third, inﬂuenza
virus vaccination studies that induce IgG
often lack pathological analysis and speciﬁc
immunohistochemical staining to visualize
virus replication in different cell types of
the nasal cavity. Since the majority of
vaccination studies target inﬂuenza virus
strains that replicate predominantly in the
respiratory mucosa, it can be assumed
that reduction of virus replication within
the nasal cavity reﬂects less virus replica-
tion in the respiratory mucosa. The effect
of vaccination on replication within the
olfactory mucosa is often not included.
The ability of vaccine-induced neutral-
izing antibodies to reduce or block inﬂu-
enza virus replication within the olfactory
mucosa is largely unknown. Different
vaccination strategies, including inacti-
vated or live-attenuated vaccines, can in-
duce either circulating IgG, mucosal
immunoglobulin A (IgA), or both [6].
Mucosal IgA is better than IgG in neu-
tralizing inﬂuenza viruses in the nasal
cavity [7]; however, the ability of mucosal
IgA to reduce or block inﬂuenza virus
replication within the olfactory mucosa
is not known.
Taken together, our knowledge of the
capacity of vaccine-induced neutralizing
antibodies to reduce or block virus repli-
cation within the olfactory mucosa is
limited. Since the endothelium within
the olfactory mucosa has a unique phe-
notype [1], it might be that neutralizing
IgG and IgA are not equally present in
the respiratory and olfactory mucosa. To
get more insight into the role of neutral-
izing antibodies after vaccination in both
the respiratory and olfactory mucosa,
these tissues should be included in future
vaccination studies for inﬂuenza viruses,
especially those with a known neurotrop-
ic potential.
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